false --12-31 0001860657 0001860657 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 12, 2026

 

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41160   87-2147982
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

 

(401) 426-4664

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ALLR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Exchange Agreement

 

On November 12, 2026, Allarity Therapeutics, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”). The Exchange Agreement relates to the Company’s Promissory Note A-1, dated March 2, 2026, in the original principal amount of $10,930,000 (the “A-1 Note”), issued pursuant to the Notes Purchase Agreement, dated March 2, 2026, between the Company and Streeterville (the “Purchase Agreement”).

 

Pursuant to the Exchange Agreement, the Company and Streeterville agreed to partition a new promissory note in the principal amount of $3,000,000 (the “Partitioned Note”) from the A-1 Note and exchange the Partitioned Note for 3,000 shares (the “Exchange Shares”) of the Company’s Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The Exchange Agreement provides that the outstanding balance of the A-1 Note is reduced by $3,000,000. The partition became effective upon acceptance of the Certificate of Designation described below by the Secretary of State of the State of Delaware. The Partitioned Note is evidenced by the Exchange Agreement, without a separate note instrument.

 

On November 16, 2026, following the filing and effectiveness of the Certificate of Designation, the Company completed the exchange and issued the Exchange Shares to Streeterville in exchange for the surrender and cancellation of the Partitioned Note. The Company received no cash proceeds from the exchange, and Streeterville provided no consideration other than the surrender of the Partitioned Note. Except as modified by the Exchange Agreement, the existing transaction documents remain in effect.

 

Series B Preferred Stock

 

In connection with the exchange, the Company’s Board of Directors approved a Certificate of Designation of Preferences and Rights of Series B Preferred Stock (the “Certificate of Designation”) on November 12, 2026. The Certificate of Designation designated 5,000 shares of Series B Preferred Stock, each with an initial stated value of $1,050 (the “Stated Value”). The 3,000 Exchange Shares have an aggregate initial Stated Value of $3,150,000. The Certificate of Designation does not provide for conversion of the Series B Preferred Stock into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

 

Each share of Series B Preferred Stock accrues a preferred return on its Stated Value at a rate of 9% per annum, compounded daily, from its issuance date (the “Preferred Return”). The Preferred Return is payable quarterly, within five trading days following the end of each calendar quarter, in cash or, at the Company’s election, in additional shares of Series B Preferred Stock. The number of additional shares is determined by dividing the accrued and unpaid Preferred Return by $1,050, with cash paid in lieu of fractional shares.

 

The Series B Preferred Stock ranks senior to the Common Stock and other junior capital stock with respect to dividends, distributions and payments upon liquidation, dissolution or winding up. Upon a liquidation, dissolution or winding up, each share is entitled to its then-applicable Stated Value plus accrued and unpaid Preferred Return, before any distribution to junior stockholders. After payment of that amount, the Series B Preferred Stock does not participate in remaining liquidation distributions and does not participate in dividends or distributions to holders of Common Stock. The Company may, at the discretion of its Board of Directors and subject to the Certificate of Designation, redeem all or a portion of the outstanding Series B Preferred Stock for cash at the same amount (the “Redemption Price”). Notice is required within ten trading days after the Board’s determination, and the redemption is to be completed on the third trading day after delivery of the notice.

 

1

 

 

The Series B Preferred Stock has no general voting rights and does not vote with the Common Stock. The Certificate of Designation requires the prior written consent of holders of a majority of the outstanding Series B Preferred Stock (the “Required Holders”) to amend or repeal the Certificate of Designation or to authorize or issue capital stock ranking senior to or pari passu with the Series B Preferred Stock as to the specified preferences.

 

While any Series B Preferred Stock remains outstanding, the Certificate of Designation imposes covenants that include maintaining the Company’s Exchange Act reporting status and a listing or quotation of the Common Stock on Nasdaq, the New York Stock Exchange or NYSE American. Subject to the terms and exceptions in the Certificate of Designation and the Side Letter described below, it also restricts additional issuances of debt or equity securities, changes to authorized capital, pledges of assets, material asset dispositions outside the ordinary course of business, certain reverse stock splits, and the entry into or consummation of a Fundamental Transaction, as defined in the Certificate of Designation. That definition includes specified business combinations, reorganizations, transfers of material assets to affiliates and distributions to stockholders outside the ordinary course of business. The reverse-stock-split restriction contains an exception for a split in connection with satisfaction of a Nasdaq deficiency notice. Additional Series B Preferred Stock may be issued only to the initial holder or its affiliates or assignees. The Company also may not enter into agreements restricting transactions with, or issuances of securities to, holders of Series B Preferred Stock or their affiliates as specified in the Certificate of Designation.

 

The restrictions on additional debt and equity issuances generally cover debt obligations other than trade payables incurred in the ordinary course of business, equity securities, and securities convertible into or exchangeable for equity securities, with an exception for issuances or sales to a holder of Series B Preferred Stock or its affiliates. The Side Letter provides a separate conditional consent for certain at-the-market sales, as described below.

 

The Required Holders may elect to declare an Event of Default upon specified covenant, payment or share-issuance defaults that remain uncured for five trading days, or upon specified bankruptcy or insolvency events. Following an Event of Default, the Preferred Return increases to 15% per annum, and the Required Holders may elect a one-time 15% increase in the Stated Value. Holders also may pursue available remedies, including injunctive relief prohibiting issuances of Common Stock or preferred stock unless their Series B Preferred Stock is simultaneously redeemed in full at the Redemption Price.

 

Side Letter

 

On November 12, 2026, the Company and Streeterville also entered into a letter agreement regarding Conditional Consent to Future Use of ATM (the “Side Letter”). Under the Side Letter, Streeterville consents to sales of Common Stock under any future at-the-market offering facility (an “ATM”), notwithstanding the restriction on issuances in Section 10(e) of the Certificate of Designation. Streeterville may revoke the consent at any time by written notice. For each week in which the Company sells Common Stock under its ATM, the Company must pay Streeterville an amount equal to 33% of the net proceeds from all sales settled during that week (each, a “Sweep Payment”).

 

Streeterville may elect to apply a Sweep Payment, in whole or in part, to redemption of its Series B Preferred Stock at the Redemption Price, repayment of the outstanding balance of the A-1 Note, or both. In the absence of an election, a Sweep Payment is applied to redemption of Series B Preferred Stock unless that redemption is not permitted by applicable law or the Certificate of Designation. Once the A-1 Note is paid in full or Streeterville no longer holds Series B Preferred Stock, the entire Sweep Payment is applied to the other obligation. Upon request, the Company must report the number of shares sold and gross proceeds from ATM sales during the preceding week. Failure to make a Sweep Payment when due constitutes an event of default under the A-1 Note and the Certificate of Designation.

 

2

 

 

The Side Letter also provides that, for purposes of note exchanges under Section 1.7 of the Purchase Agreement, the value of the Series B Preferred Stock held by Streeterville, calculated as the number of shares multiplied by the Stated Value, is included in the aggregate outstanding balance of the A Notes. The Side Letter controls in the event of a conflict with the Certificate of Designation and does not otherwise waive provisions of the parties’ other agreements or defaults under those agreements.

 

The foregoing descriptions of the Certificate of Designation, Exchange Agreement and Side Letter do not purport to be complete and are qualified in their entirety by reference to the full text of those documents, copies of which are filed as Exhibits 3.1, 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The form of certificate representing the Series B Preferred Stock is filed as Exhibit 4.1 to this Current Report on Form 8-K.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the exchange and issuance of the Exchange Shares is incorporated herein by reference. The Exchange Shares were issued in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended. The Exchange Shares were exchanged exclusively with an existing security holder of the Company for securities of the Company, and no commission or other remuneration was paid or given, directly or indirectly, for soliciting the exchange.

 

Item 3.03 Material Modification to Rights of Security Holders.

 

The information set forth in Items 1.01 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference. Upon issuance of the Exchange Shares on the closing date described in Item 1.01, the rights of holders of Common Stock became subject to the senior preferences, protective provisions and covenants applicable to the Series B Preferred Stock, including its priority with respect to dividends, distributions and payments upon liquidation, dissolution or winding up, and the restrictions on specified issuances, capital changes and transactions described above.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On November 12, 2026, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware, which became effective on November 12, 2026. The Certificate of Designation establishes the rights, preferences and limitations of a new series of 5,000 shares of Series B Preferred Stock from the Company’s authorized preferred stock. The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Certificate of Designation is incorporated herein by reference. A copy of the Certificate of Designation is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 8.01 Other Events.

 

On November 16, 2026, the Company issued a press release announcing an expansion of eligibility for its ongoing Phase 2 trial of stenoparib, a dual PARP and WNT pathway inhibitor, in advanced ovarian cancer to include patients with primary platinum-refractory disease and patients whose disease is clinically evaluable but not measurable under standard Response Evaluation Criteria in Solid Tumors. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

3

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number
  Description
3.1   Certificate of Designation of Preferences and Rights of Series B Preferred Stock of Allarity Therapeutics, Inc.
4.1   Form of Series B Preferred Stock Certificate.
10.1   Exchange Agreement, dated November 12, 2026, by and between Allarity Therapeutics, Inc. and Streeterville Capital, LLC.
10.2   Letter Agreement, dated November 12, 2026, by and between Allarity Therapeutics, Inc. and Streeterville Capital, LLC.
99.1   Press Release, dated November 16, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

4

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Allarity Therapeutics, Inc.
     
Date: November 17, 2026 By: /s/ Thomas H. Jensen
    Thomas H. Jensen
Chief Executive Officer

 

5